{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:10:21Z","timestamp":1788797421449,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"DOI":"10.1007\/s10067-026-08401-7","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:35:38Z","timestamp":1788795338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of telitacicept and belimumab in systemic lupus erythematosus: a real-word retrospective study"],"prefix":"10.1007","author":[{"given":"Mian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqing","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renju","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-0668","authenticated-orcid":false,"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"10","key":"8401_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002328","volume":"7","author":"M Larsen","year":"2011","unstructured":"Larsen M, Sauce D, Deback C et al (2011) Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 7(10):e1002328","journal-title":"PLoS Pathog"},{"issue":"2","key":"8401_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/annrheumdis-2021-221010","volume":"81","author":"HC Chuang","year":"2022","unstructured":"Chuang HC, Hung WT, Chen YM et al (2022) Genomic sequencing and functional analyses identify MAP4K3\/GLK germline and somatic variants associated with systemic lupus erythematosus. Ann Rheum Dis 81(2):243\u2013254","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8401_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2018.183","volume":"18","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Gokarn Y, Mitragotri S (2019) Non-invasive delivery strategies for biologics. Nat Rev Drug Discov 18(1):19\u201340","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"8401_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/00325481.2017.1311196","volume":"129","author":"DM Geynisman","year":"2017","unstructured":"Geynisman DM, De Velasco G, Sewell KL et al (2017) Biosimilar biologic drugs: a new frontier in medical care. Postgrad Med 129(4):460\u201370","journal-title":"Postgrad Med"},{"issue":"11","key":"8401_CR5","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48(11):3253\u20133265","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8401_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X et al (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666\u201373","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"8401_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z (2022) Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today 58(1):23\u201332","journal-title":"Drugs Today"},{"issue":"3","key":"8401_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae SC, Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77(3):355\u201363","journal-title":"Ann Rheum Dis"},{"key":"8401_CR9","unstructured":"Wu D L J, Xu D, Wang W, Li L, Fang J, Zhang F. A human recombinant fusion protein targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): results of a phase 2b study [abstract]. [J]. Arthritis Rheumatol 2019, 71."},{"issue":"1","key":"8401_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z et al (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32(1):94\u2013100","journal-title":"Lupus"},{"key":"8401_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001629","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Bae SC, Bass D et al (2021) Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001629","journal-title":"RMD Open"},{"key":"8401_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","author":"D Wu","year":"2023","unstructured":"Wu D, Li J, Xu D et al (2023) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-224854","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8401_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725","journal-title":"Arthritis Rheum"},{"key":"8401_CR14","doi-asserted-by":"crossref","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus [J].Ann Rheum Dis 2019;78(9):1151\u20139.","DOI":"10.1136\/annrheumdis-2018-214819"},{"issue":"6","key":"8401_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630\u201340","journal-title":"Arthritis Rheum"},{"key":"8401_CR16","unstructured":"Matteo Piga E C, Eric F Morand, Et Al. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study [J]. The Lancet Rheumatology, 2022, 4(6): E441-E9."},{"issue":"1","key":"8401_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA (2010) Matching methods for causal inference: a review and a look forward. Stat Sci 25(1):1\u201321","journal-title":"Stat Sci"},{"issue":"15","key":"8401_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"R Vollenhoven","year":"2025","unstructured":"Vollenhoven R, Wang L, Merrill J et al (2025) A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med 393(15):1475\u20131485","journal-title":"N Engl J Med"},{"key":"8401_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613790","volume":"16","author":"MY Liu","year":"2025","unstructured":"Liu MY, Li LJ, Li T et al (2025) Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study. Front Pharmacol 16:1613790","journal-title":"Front Pharmacol"},{"issue":"5","key":"8401_CR20","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2506","volume":"10","author":"R Furie","year":"2008","unstructured":"Furie R, Stohl W, Ginzler EM et al (2008) Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus [J]. Arthritis Res Ther 10(5):R109","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"8401_CR21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M et al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69(5):1016\u20131027","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"8401_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus [J]. Ann Rheum Dis 78(6):736\u2013745","journal-title":"Ann Rheum Dis"},{"key":"8401_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","volume":"71","author":"R Cornelis","year":"2021","unstructured":"Cornelis R, Chang HD, Radbruch A (2021) Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells [J]. Curr Opin Immunol 71:97\u2013102","journal-title":"Curr Opin Immunol"},{"issue":"17","key":"8401_CR24","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML et al (2017) Overexpression of the cytokine BAFF and autoimmunity risk [J]. N Engl J Med 376(17):1615\u20131626","journal-title":"N Engl J Med"},{"issue":"2","key":"8401_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ajmg.c.31696","volume":"181","author":"YF Wang","year":"2019","unstructured":"Wang YF, Lau YL, Yang W (2019) Genetic studies on systemic lupus erythematosus in East Asia point to population differences in disease susceptibility. Am J Med Genet C Semin Med Genet 181(2):262\u2013268","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"8401_CR26","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.2147\/DDDT.S493923","volume":"18","author":"B Liu","year":"2024","unstructured":"Liu B, Zhao Y, Liu D et al (2024) The latest progress in the application of telitacicept in autoimmune diseases[J]. Drug Des Dev Ther 18:5811\u20135825","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"8401_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.coi.2007.04.008","volume":"19","author":"F Macyay","year":"2007","unstructured":"Macyay F, Silveira PA, Brink R (2007) B cells and the BAFF\/APRIL axis: fast-forward on autoimmunity and signaling[J]. Current Opin Immunol 19(3):327\u2013336","journal-title":"Current Opin Immunol"},{"issue":"4","key":"8401_CR28","first-page":"69","volume":"29","author":"BB Reeve","year":"2008","unstructured":"Reeve BB, Smith AW, Arora NK et al (2008) Reducing bias in cancer research: application of propensity score matching [J]. Health Care Financ Rev 29(4):69\u201380","journal-title":"Health Care Financ Rev"},{"issue":"3","key":"8401_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/aje\/kwj047","volume":"163","author":"T Kurth","year":"2006","unstructured":"Kurth T, Walker AM, Glynn RJ et al (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163(3):262\u201370","journal-title":"Am J Epidemiol"},{"issue":"9","key":"8401_CR30","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1093\/cid\/ciaa169","volume":"71","author":"J Amoah","year":"2020","unstructured":"Amoah J, Stuart EA, Cosgrove SE et al (2020) Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections. Clin Infect Dis 71(9):e497\u2013e505","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08401-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08401-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08401-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:35:40Z","timestamp":1788795340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08401-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":30,"alternative-id":["8401"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08401-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Permission for conducting the human study was obtained from the Medical Ethics Committee of Nanjing Drum Tower Hospital (22\u2013353-02), and the study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}